DURHAM, N.C. and COPENHAGEN, Denmark, Oct. 21, 2022 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), EPI Health, a Novan Company, and MC2 Therapeutics right now introduced that information from a 17-question survey sponsored by the Company was revealed in a poster entitled, “Improving Patient Acceptability and Adherence in Psoriasis Treatment,” on the 42nd Annual Fall Clinical Dermatology Conference® happening October 20-23, 2022, in Las Vegas, NV.
“Topical medications continue to be a mainstay of psoriasis treatment and results from this survey provide valuable insights into what attributes patients value in these medications. This is important because treatment experience impacts patient satisfaction, adherence and ultimately, outcomes,” commented Steven R. Feldman, M.D., Ph.D., Professor of Dermatology, Wake Forest University School of Medicine.
The National Psoriasis Foundation-fielded survey was performed to evaluate psoriasis sufferers’ topical therapy expertise, expectations and preferences. Most of the contributors within the survey self-reported having average psoriasis (83.9%) and had been utilizing topical remedy a minimum of as soon as per week (76%). The sufferers reported their most bothersome signs to be scaly look (78.8%), bleeding/oozing (60%), itch (55%), and flaking (37.4%).
Nearly 80% of contributors mentioned they must discover an enchancment of their signs in two weeks or much less earlier than discontinuing a topical therapy. In addition, 75% of sufferers acknowledged they might solely persevere for a week if they didn’t like a formulation that was prescribed for them.
The formulation attributes rated most essential by these surveyed had been software really feel (55.2%), non-staining (49.9%), fast absorption (46.7%), non-sticky texture (39.7%), ease of software (28.5%), no disagreeable scent (22.4%) and non-greasy (16.8%). When requested about formulations that they had used beforehand probably the most most well-liked had been water-based cream (76%), oil-based foam (70%) and gel (48%).
“Patients expect to see rapid improvement of their symptoms, or they report they will discontinue treatment. They also want to have formulations that feel nice, absorb quickly and are non-staining, characteristics which affect their willingness to use and may be an important factor in treatment planning,” concluded Dr. Feldman.
EPI Health, a Novan firm, and MC2 Therapeutics collectively market MC2 Therapeutics’ WYNZORA® (calcipotriene and betamethasone dipropionate) Cream within the US, a once-daily aqueous cream that mixes the advantages of a excessive efficiency steroid plus Vitamin D for the therapy of plaque psoriasis. WYNZORA® Cream demonstrates a fast onset of motion with outcomes seen in efficacy, scale and itch as early as 1 week and continued enchancment at 8 weeks.2,3
Under a Promotion and Collaboration Agreement between EPI Health and MC2 Therapeutics, EPI Health has unique detailing and distribution rights and the best to collectively with MC2 Therapeutics interact in promotional, regulatory and sure commercialization actions for WYNZORA® Cream within the United States.
About WYNZORA® (calcipotriene and betamethasone dipropionate) Cream
WYNZORA® Cream is a mounted dose mixture of calcipotriene and betamethasone dipropionate indicated for the topical therapy of plaque psoriasis in adults. Betamethasone dipropionate, a high-potency corticosteroid, has anti-inflammatory results leading to decreased expression of key TNF-α, IL-17A/F and IL-23 cytokines. Calcipotriene, a vitamin-D analog, provides to the anti-inflammatory impact of the corticosteroid by mediating psoriasis particular immune-modulating exercise, stabilizes the Th2- and T-reg cell exercise and inhibits epidermal hyperproliferation. WYNZORA® Cream makes use of PAD Technology™, which uniquely permits calcipotriene and betamethasone dipropionate to be mixed in a secure, convenient-to-use aqueous formulation. WYNZORA® Cream was designed to offer one product for prime efficacy, a favorable security profile and affected person satisfaction. While their pharmacologic and scientific results are recognized, the precise mechanisms of actions of betamethasone dipropionate and calcipotriene, and WYNZORA® Cream, in plaque psoriasis are unknown.
WYNZORA® Cream – Important Safety Information
Tell your healthcare supplier about all of your medical circumstances and all of the medicines you are taking, together with any corticosteroid medicines and some other merchandise containing calcipotriene.
Do not use different merchandise containing calcipotriene or a corticosteroid drugs with out speaking to your healthcare supplier first.
WYNZORA® Cream could trigger negative effects, together with:
- Too a lot calcium in your blood or urine and/or adrenal gland issues
- Cushing’s syndrome, a situation that occurs when your physique is uncovered to giant quantities of the hormone cortisol
- High blood sugar and sugar in your urine
- Vision issues, together with an elevated threat of creating cataracts and glaucoma.
The most typical negative effects embrace higher respiratory an infection, headache, and software web site irritation. These usually are not all of the potential negative effects. Call your healthcare supplier for medical recommendation about negative effects.
This abstract is just not complete. Visit www.wynzora.com to acquire the FDA-approved Full Prescribing Information.
About Novan
Novan, Inc. is a medical dermatology firm primarily targeted on researching, creating, and commercializing modern therapeutic merchandise for pores and skin illnesses. Our purpose is to ship protected and efficacious therapies to sufferers, together with creating product candidates the place there are unmet medical wants. We are creating SB206 (berdazimer gel, 10.3%) as a topical prescription gel for the therapy of viral pores and skin infections, with present emphasis on molluscum contagiosum.
Novan lately accomplished the acquisition of EPI Health. EPI Health equips the corporate with a strong business infrastructure throughout gross sales, advertising, and communications, in addition to absolutely devoted market entry and pharmacy relation groups. Following the acquisition, the corporate employs roughly 100 employees, together with gross sales personnel at the moment masking 42 territories, and promotes merchandise for plaque psoriasis, rosacea, pimples and dermatoses. Novan additionally has a pipeline of potential product candidates utilizing our proprietary nitric oxide-based expertise platform, NITRICIL™, to generate new remedies for a number of indications.
About MC2 Therapeutics A/S
MC2 Therapeutics A/S is a privately held business stage pharmaceutical firm dedicated to analysis in pores and skin biology and improvement of novel therapy paradigms for folks with autoimmune and persistent inflammatory pores and skin circumstances.
Its modern method to handle advanced challenges extra successfully is anchored in deep understanding of the pores and skin biology mixed with learnings from the pathophysiology throughout illness segments. Fueled by an entrepreneurial mindset and creativity, MC2 Therapeutics goals to set new requirements in therapy satisfaction for folks with pores and skin circumstances.
For further info please go to www.mc2therapeutics.com
Forward-Looking Statements
Any statements contained on this press launch that don’t describe historic details could represent forward-looking statements as that time period is outlined within the Private Securities Litigation Reform Act of 1995. These statements could also be recognized by phrases resembling “believe,” “expect,” “target,” “anticipate,” “may,” “plan,” “potential,” “will,” “look forward to” and related expressions, and are primarily based on the Company’s present beliefs and expectations. These forward-looking statements embrace, however usually are not restricted to, statements associated to the potential advantages of the acquisition of EPI Health, the therapeutic worth and advantages of the Company’s promoted merchandise, together with WYNZORA® Cream, the potential therapeutic worth and advantages of the Company’s Nitricil™ platform expertise and its product candidates, the potential market alternative for the Company’s product candidates and promoted merchandise, the Company’s pharmaceutical improvement of nitric oxide-releasing product candidates, resembling berdazimer gel, 10.3% (SB206) for molluscum contagiosum, the timing of regulatory filings, and the provision of potential financing choices. Forward-looking statements are topic to a variety of dangers and uncertainties that might trigger precise outcomes to vary materially from the Company’s expectations, together with, however not restricted to, dangers associated to the acquisition of EPI Health; dangers associated to the regulatory approval course of, which is prolonged, time-consuming and inherently unpredictable, together with the chance that the FDA is not going to agree with the Company’s method to a potential NDA submission, that the Company’s product candidates is probably not authorised or that further research could also be required for approval or different delays could happen, that the Company could not have enough portions of drug substance and/or drug product to help regulatory submissions and that the Company could not receive funding enough to increase its money runway or to finish the regulatory or improvement course of; the Company’s restricted expertise as a firm in acquiring regulatory approvals for and launching merchandise developed internally and its means to recruit and retain certified personnel and key expertise; adjustments within the dimension and nature of the marketplace for the Company’s product candidates and promoted merchandise, together with potential competitors, affected person and payer perceptions and reimbursement determinations; the Company’s means to develop revenues from promoted merchandise and the dangers that previous efficiency is probably not indicative of future efficiency; dangers and uncertainties within the Company’s ongoing or future product improvement actions and preclinical research, which can not show profitable in demonstrating proof-of idea, or could present adversarial toxicological findings, and even when profitable could not essentially predict that subsequent scientific trials will present the requisite security and efficacy of the Company’s product candidates, or that any of the Company’s product candidates, if authorised, will proceed to show requisite security and efficacy following their business launch; any operational or different disruptions as a results of the COVID-19 pandemic; dangers associated to the manufacture of uncooked supplies and completed drug product, resembling provide chain disruptions or delays, failure to switch expertise and processes to 3rd events successfully or failure of these third events (or the Company in reference to the Company’s facility) to acquire approval of and preserve compliance with the FDA or comparable regulatory authorities; the Company’s reliance on preparations with third events to help its operations and its improvement, manufacturing and commercialization efforts and the chance that such events is not going to efficiently perform their contractual duties or meet anticipated deadlines; the Company’s means to acquire further funding or enter into strategic or different business relationships vital or helpful for the additional improvement or commercialization of the Company’s product candidates and the operation of its business on phrases which are acceptable to the Company or in any respect or if such relationships or transactions are unsuccessful or the Company is unable to understand the potential financial advantages of such relationships or transactions; and different dangers and uncertainties described within the Company’s annual report filed with the Securities and Exchange Commission on Form 10-Okay for the twelve months ended December 31, 2021, and within the Company’s subsequent filings with the Securities and Exchange Commission. Such forward-looking statements converse solely as of the date of this press launch, and the Company disclaims any intent or obligation to replace these forward-looking statements to mirror occasions or circumstances after the date of such statements, besides as could also be required by regulation.
INVESTOR AND MEDIA CONTACT:
Jenene Thomas
JTC Team, LLC
833-475-8247
[email protected]
Sam Widdicombe
EPI Health, LLC
[email protected]
949-331-0269
Lonni Goltermann
MC2 Therapeutics
[email protected]
+45 2018 1111
References:
1 Wynzora® Cream [package insert]. MC2 Therapeutics; 2020
2 Han et al. Poster Presentation. SKIN Vol 6 (4) 2022: S42
